Literature DB >> 16670300

Further differentiation of murine double-positive thymocytes is inhibited in adenosine deaminase-deficient murine fetal thymic organ culture.

C Justin Van De Wiele1, Michelle L Joachims, Amy M Fesler, James G Vaughn, Michael R Blackburn, Stephanie T McGee, Linda F Thompson.   

Abstract

Murine fetal thymic organ culture (FTOC) was used to investigate the mechanism by which a lack of adenosine deaminase (ADA) leads to a failure of T cell production in the thymus. We previously showed that T cell development was inhibited beginning at the CD4(-)CD8(-)CD25(+)CD44(low) stage in ADA-deficient FTOC initiated at day 15 of gestation when essentially all thymocytes are CD4(-)CD8(-). In the present study, we asked whether thymocytes at later stages of differentiation would also be sensitive to ADA inhibition by initiating FTOC when substantial numbers of CD4(+)CD8(+) thymocytes were already present. dATP was highly elevated in ADA-deficient cultures, and the recovery of alphabeta TCR(+) thymocytes was inhibited by 94%, indicating that the later stages of thymocyte differentiation are also dependent upon ADA. ADA-deficient cultures were partially rescued by the pan-caspase inhibitor carbobenzoxy-Val-Ala-Asp-fluoromethyl ketone or by the use of apoptotic protease-activating factor-1-deficient mice. Rescue was even more dramatic, with 60- to >200-fold increases in the numbers of CD4(+)CD8(+) cells, when FTOC were performed with an inhibitor of adenosine kinase, the major thymic deoxyadenosine phosphorylating enzyme, or with bcl-2 transgenic mice. dATP levels were normalized by treatment with either carbobenzoxy-Val-Ala-Asp-fluoromethyl ketone or an adenosine kinase inhibitor, but not in cultures with fetal thymuses from bcl-2 transgenic mice. These data suggest that ADA deficiency leads to the induction of mitochondria-dependent apoptosis as a consequence of the accumulation of dATP derived from thymocytes failing the positive/negative selection checkpoint.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16670300      PMCID: PMC1550651          DOI: 10.4049/jimmunol.176.10.5925

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Immature thymocytes employ distinct signaling pathways for allelic exclusion versus differentiation and expansion.

Authors:  F Gärtner; F W Alt; R Monroe; M Chu; B P Sleckman; L Davidson; W Swat
Journal:  Immunity       Date:  1999-05       Impact factor: 31.745

2.  Adenosine kinase from rabbit liver. II. Substrate and inhibitor specificity.

Authors:  R L Miller; D L Adamczyk; W H Miller; G W Koszalka; J L Rideout; L M Beacham; E Y Chao; J J Haggerty; T A Krenitsky; G B Elion
Journal:  J Biol Chem       Date:  1979-04-10       Impact factor: 5.157

3.  Marking emerging beta- and gammadelta-selected T cells.

Authors:  Cornelis Murre
Journal:  Immunity       Date:  2006-01       Impact factor: 31.745

4.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).

Authors:  D A Carson; J Kaye; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

5.  Age and stage dependency of estrogen receptor expression by lymphocyte precursors.

Authors:  H Igarashi; T Kouro; T Yokota; P C Comp; P W Kincade
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

6.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

7.  Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors.

Authors:  R P Agarwal; T Spector; R E Parks
Journal:  Biochem Pharmacol       Date:  1977-03-01       Impact factor: 5.858

8.  Metabolites from apoptotic thymocytes inhibit thymopoiesis in adenosine deaminase-deficient fetal thymic organ cultures.

Authors:  L F Thompson; C J Van de Wiele; A B Laurent; S W Hooker; J G Vaughn; H Jiang; K Khare; R E Kellems; M R Blackburn; M S Hershfield; R Resta
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

9.  Adenosine kinase inhibition promotes survival of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulation.

Authors:  C Justin Van De Wiele; James G Vaughn; Michael R Blackburn; Catherine A Ledent; Marlene Jacobson; Hong Jiang; Linda F Thompson
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 10.  Mechanisms of apoptosis in developing thymocytes as revealed by adenosine deaminase-deficient fetal thymic organ cultures.

Authors:  Linda F Thompson; James G Vaughn; Aletha B Laurent; Michael R Blackburn; C Justin Van De Wiele
Journal:  Biochem Pharmacol       Date:  2003-10-15       Impact factor: 5.858

View more
  5 in total

1.  Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.

Authors:  Olga Nikolajeva; Austen Worth; Rosie Hague; Nuria Martinez-Alier; Joanne Smart; Stuart Adams; E Graham Davies; H Bobby Gaspar
Journal:  J Clin Immunol       Date:  2015-04-15       Impact factor: 8.317

2.  Restoration of adenosine deaminase-deficient human thymocyte development in vitro by inhibition of deoxynucleoside kinases.

Authors:  Michelle L Joachims; Patrick A Marble; Aletha B Laurent; Peter Pastuszko; Marco Paliotta; Michael R Blackburn; Linda F Thompson
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

3.  Impaired thymopoiesis in interleukin-7 receptor transgenic mice is not corrected by Bcl-2.

Authors:  C Justin Van de Wiele; Julie H Marino; Chibing Tan; Hilary A Kneale; John Weber; John N Morelli; Brenda K Davis; Ashlee A Taylor; T Kent Teague
Journal:  Cell Immunol       Date:  2008-03-05       Impact factor: 4.868

4.  Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency.

Authors:  Aisha Vanessa Sauer; Immacolata Brigida; Nicola Carriglio; Alessandro Aiuti
Journal:  Front Immunol       Date:  2012-08-27       Impact factor: 7.561

5.  Profile of circulating microRNAs in myalgic encephalomyelitis and their relation to symptom severity, and disease pathophysiology.

Authors:  Evguenia Nepotchatykh; Wesam Elremaly; Iurie Caraus; Christian Godbout; Corinne Leveau; Lynda Chalder; Catherine Beaudin; Emi Kanamaru; Renata Kosovskaia; Shawn Lauzon; Yanick Maillet; Anita Franco; Viorica Lascau-Coman; Saadallah Bouhanik; Yaned Patricia Gaitan; Dawei Li; Alain Moreau
Journal:  Sci Rep       Date:  2020-11-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.